How old is effexor

Should the decision be made to treat a pediatric patient with Effexor XR, regular monitoring of weight and height is recommended during treatment, particularly if treatment is to be continued long-term [see Warnings and Precautions 5. The safety of Effexor XR treatment for pediatric patients has not been systematically assessed for chronic treatment longer than six months in duration.

In the studies conducted in pediatric patients ages 6—17 , the occurrence of blood pressure and cholesterol increases considered to be clinically relevant in pediatric patients was similar to that observed in adult patients.

Consequently, the precautions for adults apply to pediatric patients [see Warnings and Precautions 5. No overall differences in effectiveness or safety were observed between geriatric patients and younger patients, and other reported clinical experience generally has not identified differences in response between the elderly and younger patients.

However, greater sensitivity of some older individuals cannot be ruled out. The pharmacokinetics of venlafaxine and ODV are not substantially altered in the elderly [see Clinical Pharmacology No dose adjustment is recommended for the elderly on the basis of age alone, although other clinical circumstances, some of which may be more common in the elderly, such as renal or hepatic impairment, may warrant a dose reduction [see Dosage and Administration 2.

A population pharmacokinetic analysis of Effexor-treated patients from two studies involving both twice daily and three times daily regimens showed that dose-normalized trough plasma levels of either venlafaxine or ODV were unaltered by age or gender differences. Dosage adjustment based on the age or gender of a patient is generally not necessary [see Dosage and Administration 2. While venlafaxine has not been systematically studied in clinical studies for its potential for abuse, there was no indication of drug-seeking behavior in the clinical studies.

Consequently, physicians should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of venlafaxine e. Venlafaxine was not found to have any significant CNS stimulant activity in rodents. In primate drug discrimination studies, venlafaxine showed no significant stimulant or depressant abuse liability.

Discontinuation effects have been reported in patients receiving venlafaxine [see Dosage and Administration 2. Somnolence was the most commonly reported symptom. Among the other reported symptoms were paresthesia of all four limbs, moderate dizziness, nausea, numb hands and feet, and hot-cold spells 5 days after the overdose. In most cases, no signs or symptoms were associated with overdose. The majority of the reports involved ingestion in which the total dose of venlafaxine taken was estimated to be no more than several-fold higher than the usual therapeutic dose.

One patient who ingested 2. Mild sinus tachycardia was reported in two of the other patients. Actions taken to treat the overdose included no treatment, hospitalization and symptomatic treatment, and hospitalization plus treatment with activated charcoal.

All patients recovered. The most commonly reported events in overdosage include tachycardia, changes in level of consciousness ranging from somnolence to coma , mydriasis, seizures, and vomiting. Electrocardiogram changes e. Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants.

Epidemiological studies have shown that venlafaxine-treated patients have a higher preexisting burden of suicide risk factors than SSRI-treated patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdosage, as opposed to some characteristic s of venlafaxine-treated patients, is not clear.

Consult a Certified Poison Control Center for up-to-date guidance and advice or www. In case of an overdose, provide supportive care, including close medical supervision and monitoring. Treatment should consist of those general measures employed in the management of overdosage with any drug. Consider the possibility of multiple drug overdose. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs.

Provide supportive and symptomatic measures. Effexor XR is an extended-release capsule for once-a-day oral administration that contains venlafaxine hydrochloride, a SNRI. Its molecular weight is The structural formula is shown as follows:. Its octanol:water 0. Drug release is controlled by diffusion through the coating membrane on the spheroids and is not pH-dependent.

Capsules contain venlafaxine hydrochloride equivalent to Inactive ingredients consist of cellulose, ethylcellulose, gelatin, hypromellose, iron oxide, and titanium dioxide. The exact mechanism of the antidepressant action of venlafaxine in humans is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake.

Non- clinical studies have demonstrated that venlafaxine and its active metabolite, ODV, are potent and selective inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake. Pharmacologic activity at these receptors is hypothesized to be associated with the various anticholinergic, sedative, and cardiovascular effects seen with other psychotropic drugs.

The effect of venlafaxine on the QT interval was evaluated in a randomized, double-blind, placebo- and positive-controlled three-period crossover thorough QT study in 54 healthy adult subjects. No significant QT prolongation effect of venlafaxine mg was detected. Steady-state concentrations of venlafaxine and ODV in plasma are attained within 3 days of oral multiple-dose therapy.

Venlafaxine and ODV exhibited linear kinetics over the dose range of 75 to mg per day. Venlafaxine is well absorbed and extensively metabolized in the liver. ODV is the major active metabolite. Administration of Effexor XR mg once daily generally resulted in lower C max and later T max values than for Effexor immediate release administered twice daily Table When equal daily doses of venlafaxine were administered as either an immediate-release tablet or the extended-release capsule, the exposure to both venlafaxine and ODV was similar for the two treatments, and the fluctuation in plasma concentrations was slightly lower with the Effexor XR capsule.

Therefore, Effexor XR provides a slower rate of absorption, but the same extent of absorption compared with the immediate-release tablet. Food did not affect the bioavailability of venlafaxine or its active metabolite, ODV. Venlafaxine is not highly bound to plasma proteins; therefore, administration of Effexor XR to a patient taking another drug that is highly protein-bound should not cause increased free concentrations of the other drug.

Following absorption, venlafaxine undergoes extensive presystemic metabolism in the liver, primarily to ODV, but also to N-desmethylvenlafaxine, N,O-didesmethylvenlafaxine, and other minor metabolites.

Renal elimination of venlafaxine and its metabolites is thus the primary route of excretion. Tumors were not increased by venlafaxine treatment in mice or rats. Plasma levels of the O-desmethyl metabolite ODV were lower in rats than in patients receiving the maximum recommended dose. O-desmethylvenlafaxine ODV , the major human metabolite of venlafaxine, administered by oral gavage to mice and rats for 2 years did not increase the incidence of tumors in either study.

ODV was not clastogenic in the in vitro Chinese hamster ovary cell chromosomal aberration assay or in the in vivo chromosomal aberration assay in rats. However, reduced fertility was observed in a study in which male and female rats were treated with O-desmethylvenlafaxine ODV , the major human metabolite of venlafaxine, prior to and during mating and gestation.

In moderately depressed outpatients, the initial dose of venlafaxine was 75 mg per day. In both studies, Effexor XR demonstrated superiority over placebo on the primary efficacy measure defined as change from baseline in the HAM-D total score to the endpoint visit, Effexor XR also demonstrated superiority over placebo on the key secondary efficacy endpoint, the Clinical Global Impressions CGI Severity of Illness scale.

Examination of gender subsets of the population studied did not reveal any differential responsiveness on the basis of gender. The mean dose in completers was mg per day study 3. In a longer-term study, adult outpatients with MDD who had responded during an 8-week open-label study on Effexor XR 75, , or mg, once daily every morning were randomized to continuation of their same Effexor XR dose or to placebo, for up to 26 weeks of observation for relapse.

Patients receiving continued Effexor XR treatment experienced statistically significantly lower relapse rates over the subsequent 26 weeks compared with those receiving placebo study 4. Patients receiving continued Effexor treatment experienced statistically significantly lower relapse rates over the subsequent 52 weeks compared with those receiving placebo study 5.

The efficacy of Effexor XR as a treatment for Generalized Anxiety Disorder GAD was established in two 8-week, placebo-controlled, fixed-dose studies 75 to mg per day , one 6-month, placebo-controlled, flexible-dose study 75 to mg per day , and one 6-month, placebo-controlled, fixed-dose study However, the 75 and mg per day doses were not as consistently effective as the highest dose study 1.

A second 8-week study evaluating doses of 75 and mg per day and placebo showed that both doses were more effective than placebo on some of these same outcomes; however, the 75 mg per day dose was more consistently effective than the mg per day dose study 2.

A dose-response relationship for effectiveness in GAD was not clearly established in the 75 to mg per day dose range studied. Two 6-month studies, one evaluating Effexor XR doses of While there was also evidence for superiority over placebo for the There was no evidence for any greater effectiveness of the to mg per day group compared to the 75 mg per day group in the 6-month study. Examination of subsets of the population studied did not reveal any differential responsiveness on the basis of gender.

There was insufficient information to determine the effect of age or race on outcome in these studies. Patients received fixed doses of 75 or mg per day in one study study 1 and 75 or mg per day in the other study study 2. Efficacy was assessed on the basis of outcomes in three variables: 1 percentage of patients free of full-symptom panic attacks on the Panic and Anticipatory Anxiety Scale PAAS ; 2 mean change from baseline to endpoint on the Panic Disorder Severity Scale PDSS total score; and 3 percentage of patients rated as responders much improved or very much improved on the Clinical Global Impressions CGI Improvement scale.

In these two studies, Effexor XR was statistically significantly more effective than placebo for each fixed dose on all three endpoints, but a dose-response relationship was not clearly established. In a longer term study study 3 , adult outpatients meeting DSM-IV criteria for PD who had responded during a week open phase with Effexor XR 75 to mg per day were randomly assigned to continue the same Effexor XR dose 75, , or mg or switch to placebo for observation for relapse under double-blind conditions.

Relapse during the double-blind phase was defined as having 2 or more full-symptom panic attacks per week for 2 consecutive weeks or having discontinued due to loss of effectiveness as determined by the investigators during the study. Randomized patients were in response status for a mean time of 34 days prior to being randomized. In the randomized phase following the week open-label period, patients receiving continued Effexor XR experienced a statistically significantly longer time to relapse.

Two placebo-controlled studies in pediatric patients with MDD and two placebo-controlled studies in pediatric patients with GAD have been conducted with Effexor XR, and the data were not sufficient to support a claim for use in pediatric patients. Prescribers or other healthcare professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with Effexor XR and should counsel them in its appropriate use. The prescriber or healthcare professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents.

Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document. Patients should be advised of the following issues and should be asked to alert their prescriber if these occur while taking Effexor XR.

Advise patients, their families and caregivers to look for the emergence of suicidality, worsening of depression, and other psychiatric symptoms anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, psychomotor restlessness, hypomania, mania, other unusual changes in behavior , especially early during treatment and when the dose is adjusted up or down.

Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring [see Boxed Warning and Warnings and Precautions 5.

Advise patients taking Effexor XR not to use concomitantly other products containing venlafaxine or desvenlafaxine. Patients should be cautioned about the risk of serotonin syndrome, with the concomitant use of Effexor XR and triptans, tramadol, amphetamines, tryptophan supplements, with antipsychotics or other dopamine antagonists, or other serotonergic agents [ s ee Warnings and Precautions 5.

Advise patients that they should have regular monitoring of blood pressure when taking Effexor XR [see Warnings and Precautions 5. Patients should be cautioned about the concomitant use of Effexor XR and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation since combined use of psychotropic drugs that interfere with serotonin reuptake and these agents has been associated with an increased risk of bleeding [see Warnings and Precautions 5.

Patients should be advised that taking Effexor XR can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle closure glaucoma. Pre-existing glaucoma is almost always open-angle glaucoma because angle closure glaucoma, when diagnosed, can be treated definitively with iridectomy.

No matter your age, before you take an antidepressant, you, your parent, or your caregiver should talk to your doctor about the risks and benefits of treating your condition with an antidepressant or with other treatments.

You should also talk about the risks and benefits of not treating your condition. You should know that having depression or another mental illness greatly increases the risk that you will become suicidal. This risk is higher if you or anyone in your family has or has ever had bipolar disorder mood that changes from depressed to abnormally excited or mania frenzied, abnormally excited mood or has thought about or attempted suicide.

Talk to your doctor about your condition, symptoms, and personal and family medical history. You and your doctor will decide what type of treatment is right for you. Venlafaxine is used to treat depression. Venlafaxine extended-release long-acting capsules are also used to treat generalized anxiety disorder GAD; excessive worrying that is difficult to control , social anxiety disorder extreme fear of interacting with others or performing in front of others that interferes with normal life , and panic disorder sudden, unexpected attacks of extreme fear and worry about these attacks.

Venlafaxine is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors SNRIs. It works by increasing the amounts of serotonin and norepinephrine, natural substances in the brain that help maintain mental balance. Venlafaxine comes as a tablet or extended-release capsule to take by mouth.

The tablet is usually taken two or three times a day with food. The extended-release capsule is usually taken once daily in the morning or evening with food. Take venlafaxine at around the same time s every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take venlafaxine exactly as directed. Do not take more or less of it or take it more often or for a longer period of time than prescribed by your doctor.

Swallow the extended-release capsule whole; do not split, chew, or crush it, or place it in water. If you cannot swallow the extended-release capsule, you may carefully open the capsule and sprinkle the entire contents on a spoonful of applesauce.

Swallow without chewing this mixture immediately after preparation and then drink a glass of water to make sure that you have swallowed all of the medication. Your doctor will probably start you on a low dose of venlafaxine and gradually increase your dose, not more often than once every 4 to 7 days. Tell your doctor how you are feeling during your treatment so that your doctor can adjust your dose properly.

Venlafaxine controls depression but does not cure it. It may take 6 to 8 weeks or longer for you to feel the full benefit of this medication. Continue to take venlafaxine even if you feel well. You should always consult your doctor or other healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects.

The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses. Panic attacks can be sudden and overpowering.

Knowing what to do can help people regain control. This article looks at 13 ways to stop a panic attack. Cannabidiol, or CBD, is a compound that comes from the cannabis plant. It is gaining popularity as a natural treatment for many mental health…. Certain situations and events can be anxiety triggers for some people. Strategies are available to help people avoid triggers and get their anxiety….

Previous research has shown that some natural supplements — including vitamins, omega-3 fatty acids, and herbal remedies such as valerian and…. Antidepressants are a commonly used drug in the United States, but some people find they gain or lose weight when using specific types. The link is…. Effexor XR venlafaxine. What is Effexor XR?

Effexor XR uses. Effexor XR generic. Effexor XR contains the active drug ingredient venlafaxine. Effexor XR side effects. Serious side effects and their symptoms can include the following: Seizures. Serotonin syndrome high levels of serotonin, a chemical in your brain.

Symptoms can include: anxiety shakiness fever diarrhea fast heartbeat seizures High blood pressure. Symptoms can include: headache shortness of breath Abnormal bleeding. Symptoms can include: bruising easily and often nosebleeds coughing up blood producing vomit that looks like coffee grounds blood in your stool black or tarry stool Hyponatremia low sodium levels. Symptoms can include: headache trouble focusing weakness feeling unsteady fainting seizures Lung disease and pneumonia. Symptoms can include: shortness of breath cough pain in your chest fever Withdrawal symptoms if you stop taking the drug suddenly.

Suicidal thoughts and behaviors in children and young adults. Side effect details You may wonder how often certain side effects occur with this drug. Allergic reaction As with most drugs, some people can have an allergic reaction after taking Effexor XR. Symptoms of a mild allergic reaction can include: skin rash itchiness flushing warmth and redness in your skin A more severe allergic reaction is rare but possible. Symptoms of a severe allergic reaction can include: swelling under your skin, typically in your eyelids, lips, hands, or feet swelling of your tongue, mouth, or throat trouble breathing Call your doctor right away if you have a severe allergic reaction to Effexor XR.

Weight gain or weight loss Weight gain and weight loss have occurred in clinical studies of Effexor XR. Nausea Nausea is a common side effect of Effexor XR.

Insomnia Insomnia trouble sleeping is a common side effect of Effexor XR. Suicidal thoughts and behaviors in young people There is an increased risk of suicidal thoughts and behavior in young people up to 24 years old who take antidepressants, including Effexor XR. Note: Effexor XR is not approved for use in children younger than 18 years old. Side effects in children Effexor XR is not approved for use in children under 18 years old.

Weight loss in children In clinical studies lasting 8 to 16 weeks, many children who took Effexor XR had a lack of appetite.

Slowed growth in children In clinical studies , children who took Effexor XR grew in height more slowly than typical children in their age group. Effexor XR dosage. The Effexor XR dosage your doctor prescribes will depend on several factors. You take it with food. It comes in three strengths: Dosage for generalized anxiety disorder The usual starting dosage of Effexor XR for generalized anxiety disorder GAD is 75 mg once daily. Dosage for social anxiety disorder The standard dosage of Effexor XR for social anxiety disorder is 75 mg once daily.

Dosage for panic disorder The usual starting dosage of Effexor XR for panic disorder is What if I miss a dose? Will I need to use this drug long term? Effexor XR withdrawal. These symptoms can include: anxiety feeling agitated confusion flu-like symptoms insomnia trouble sleeping shakiness diarrhea nausea vomiting To avoid withdrawal symptoms, your dosage of Effexor XR should be tapered gradually decreased over several weeks.

Effexor XR and alcohol. Alternatives to Effexor XR. Effexor XR interactions. Taking Effexor XR with St. Tryptophan also called 5-HTP is a supplement used to improve mood and sleep quality. Taking Effexor XR with tryptophan can increase your risk for serotonin syndrome see below. About serotonin syndrome Serotonin syndrome is a serious reaction that happens when too much serotonin a chemical produced by nerve cells builds up in your body.

Common questions about Effexor XR. Here are answers to some frequently asked questions about Effexor XR. Is the immediate-release form of Effexor available? Is Effexor XR a stimulant? Effexor XR and pregnancy. Effexor XR and birth control. Effexor XR and breastfeeding. How Effexor XR works. How long does it take to work? Effexor XR cost. As with all medications, the cost of Effexor XR can vary. Financial and insurance assistance If you need financial support to pay for Effexor XR, or if you need help understanding your insurance coverage, help is available.

How to take Effexor XR. When to take Effexor XR is taken once a day. Can Effexor XR be crushed, split, or chewed? No, Effexor XR should not be crushed, split, or chewed. Effexor XR precautions. This drug comes with several warnings.

FDA warning: Increased risk of suicidal thoughts and behavior in young people This drug has a boxed warning. Other precautions Before taking Effexor XR, talk with your doctor about your health history. These include: Bipolar disorder or mania. The most effective drug for you should be determined by your healthcare provider, who can take into account your medical history, medical conditions, and other medications you take that could interact with Effexor or Zoloft.

Effexor XR, the more popularly prescribed type of Effexor, is covered by most insurance and Medicare prescription plans. The generic version will have a lower copay, and the brand name may have a higher copay or may not be covered. Zoloft is usually covered by both insurance and Medicare prescription plans. Generic Zoloft will have a lower copay, whereas brand name may have a higher copay or may not be covered at all.

As insurance plans vary and are subject to change, contact your health insurance plan for current coverage information. The most common side effects of Effexor XR are nausea, sleepiness, dry mouth, sweating, sexual problems, decreased appetite, and constipation. The most common adverse reactions of Zoloft are nausea, diarrhea, sexual problems, dry mouth, insomnia, and sleepiness. Other adverse effects may occur. Consult your healthcare professional for a complete list of side effects.

MAO inhibitors should not be used within 14 days of Effexor or Zoloft. The combination may increase the risk of serotonin syndrome , a life-threatening medical emergency due to excess serotonin.

Triptans used to treat migraines, as well as other antidepressants, opioids, dextromethorphan, or St. Nonsteroidal anti-inflammatory drugs NSAIDs such as Advil, Motrin, and aspirin, or anticoagulants such as warfarin, should not be taken with Effexor or Zoloft because of increased bleeding risk. Other drug interactions may occur. Consult your healthcare provider for a full list of drug interactions.

Effexor is an SNRI antidepressant. Effexor treats depression also called major depressive disorder or major depression in adults. Effexor XR extended-release treats depression, social anxiety disorder, panic disorder, and generalized anxiety disorder. The generic name of Effexor is venlafaxine. Zoloft sertraline is an SSRI selective serotonin reuptake inhibitor indicated for the treatment of major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder.